Article Details

New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with ...

Retrieved on: 2022-06-03 16:23:40

Tags for this article:

Click the tags to see associated articles and topics

New CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with .... View article details on hiswai:

Excerpt

These data will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. In a new exploratory analysis of data from the ...

Article found on: www.novartis.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up